Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward
ConclusionsDespite a large body of health economics evidence on non-surgical biomedical HIV prevention technologies, important gaps in the scope of evidence and methodology remain. To ensure that high-quality research influences key decision-making junctures and facilitates the delivery of prevention products in a way that maximises impact, we make five broad recommendations related to: improved study design, an increased focus on service delivery, greater community and stakeholder engagement, the fostering of an active network of partners across sectors and an enhanced application of research. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 11, 2023 Category: Health Management Source Type: research
Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review
ConclusionThe net health impact of constraints is vital evidence to help decision-makers scale up the delivery of cell and gene therapies as patient volume increases and more advanced therapy medicinal products are launched. CEAs will be essential to quantify how constraints affect the cost-effectiveness of care, prioritise constraints to be resolved, and establish the value of strategies to implement cell and gene therapies by accounting for their health opportunity cost. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 11, 2023 Category: Health Management Source Type: research
Cost Effectiveness of Pharmacological and Non-pharmacological Treatments for Depression in Low- and Middle-Income Countries: A Systematic Literature Review
ConclusionsOverall, this review found mixed evidence on the cost effectiveness of depression treatment choices among LMICs, with some indication that task sharing with lay health workers may be cost effective. Future research will be needed to fill the gaps around the cost effectiveness of depression treatments in younger people and beyond healthcare facilities. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 9, 2023 Category: Health Management Source Type: research
Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review
ConclusionsThe variation in natural history model structures and the lack of data for model parameterisation suggest that research in bladder cancer early detection and screening is at an early stage of development. Appropriate characterisation and analysis of uncertainty in bladder cancer models should be considered a priority. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 8, 2023 Category: Health Management Source Type: research
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Na ïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
ConclusionThe current analysis suggests that the treatment pattern including 1L tofacitinib is a cost-effective alternative to the biologics for patients with moderate-to-severe UC from a Japanese payer ’s perspective. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 8, 2023 Category: Health Management Source Type: research
Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review
ConclusionsThe variation in natural history model structures and the lack of data for model parameterisation suggest that research in bladder cancer early detection and screening is at an early stage of development. Appropriate characterisation and analysis of uncertainty in bladder cancer models should be considered a priority. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 8, 2023 Category: Health Management Source Type: research
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Na ïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
ConclusionThe current analysis suggests that the treatment pattern including 1L tofacitinib is a cost-effective alternative to the biologics for patients with moderate-to-severe UC from a Japanese payer ’s perspective. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 8, 2023 Category: Health Management Source Type: research
Associating Health-Related Quality-of-Life Score with Time Uses to Inform Productivity Measures in Cost-Effectiveness Analysis
ConclusionOur estimates can facilitate the inclusion of productivity and time spent seeking care in CEA as recommended by the Second Panel. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 6, 2023 Category: Health Management Source Type: research
The Cost of Uncontrolled Blood Pressure in Australian General Practice: A Modelling Study Using Electronic Health Records (MedicineInsight)
ConclusionsThe aggregate cost effects of poor blood pressure control in primary care are high, but cost implications at the individual practice level are modest. The potential cost savings improve the potential to design cost-effective interventions, but such interventions may be best targeted at a population level rather than at individual practices.Graphical Abstract (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 4, 2023 Category: Health Management Source Type: research
Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review
(Source: PharmacoEconomics)
Source: PharmacoEconomics - March 4, 2023 Category: Health Management Source Type: research
The Cost of Uncontrolled Blood Pressure in Australian General Practice: A Modelling Study Using Electronic Health Records (MedicineInsight)
ConclusionsThe aggregate cost effects of poor blood pressure control in primary care are high, but cost implications at the individual practice level are modest. The potential cost savings improve the potential to design cost-effective interventions, but such interventions may be best targeted at a population level rather than at individual practices.Graphical Abstract (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 4, 2023 Category: Health Management Source Type: research
Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review
(Source: PharmacoEconomics)
Source: PharmacoEconomics - March 4, 2023 Category: Health Management Source Type: research
Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects
ConclusionsThis study highlights that compensation mechanisms and multiplier effects are common and may substantially affect production losses. Investigating these mechanisms and effects further, as well as their interactions, remains important. Translating these findings into productivity cost calculations in economic evaluations is not straightforward and requires attention, especially since compensation mechanisms may not be costless and, for multiplier effects, the value of hours of colleagues may not be similar to that of the person experiencing health problems. (Source: PharmacoEconomics)
Source: PharmacoEconomics - March 1, 2023 Category: Health Management Source Type: research
